Sai Life Sciences to Double R&D Capacity with New Hyderabad Facility

Hyderabad, 27 October 2025 – Sai Life Sciences Ltd (BSE: 544306 | NSE: SAILIFE) has announced that a new CMC Process Research and Development Center is going to be built at the company’s integrated research and development campus in Hyderabad.

The new facility is expected to be in service by September 2026. The addition of this facility is expected to double the Company’s Process R&D capacity and provide new capabilities for peptide development, oligo intermediates, formulation development, and early-phase clinical supplies.

As of 27 October 2025, Sai Life Sciences Ltd share finished at ₹877.10, down 17.95 or 2.01% from its previous close of ₹895.05. The share traded at a high of ₹895.80 and a low of ₹874.85 in the session.

Expansion Highlights

The recently constructed 100,000 sq. ft. facility has five floors, featuring 140 process chemistry fume hoods, dedicated peptide and oligo labs, and a 25,000 sq. ft. central analytical lab. The facility supports NCE formulation and early phase clinical manufacturing (OEL 4 containment) in a sustainable, green-certified building.

The initiative is part of Sai Life Sciences’ planned capital expenditures program to expand its CMC capacity to meet growing international demand for late-stage development and larger-scale clinical manufacturing.

Management Commentary

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said,

“As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum. This new center enhances our ability to combine scientific excellence with execution agility.”

Sai Life Sciences Limited is a comprehensive Contract Research, Development & Manufacturing Organization (CRDMO) that provides services to pharmaceutical and biotechnology innovators worldwide. Based in Hyderabad and with operations in the UK, the US, and across India, the company is dedicated to accelerating the discovery and commercialization of small molecules and emerging modalities, with a strong focus on quality, safety, and sustainability.

REF: https://nsearchives.nseindia.com/corporate/SAILIFE_27102025153503_LODR_Press_Release_F.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations